EuropaBio

Biotechnology and bioeconomy are key cross sectoral circularity enablers that rely on renewable raw materials, enhancing resource efficiency while adding value in the process. The Circular Economy Act must foster a holistic, coherent and supportive policy framework for biotechnologies.

EuropaBio welcomes the European Commission commitment to initiate the Industrial Decarbonisation Accelerator (IDA) Act as part of the Clean Industrial Deal. Biotechnology and biomanufacturing are of high strategic importance to achieve the EUs net-zero ambitions and should be included in the IDA Act as essential for EU competitiveness. This would also boost industrial confidence.

EuropaBio, the industry association for biotechnology in Europe, welcomes the opportunity to contribute to the evaluation of the public procurement Directive 2014/24/EU. Please see our full response in the attached file. Biotechnologies play an essential and significant role for the delivery of EU goals for competitive, healthy, resilient and sustainable economies and societies.

EuropaBio, the industry association for biotechnology in Europe, welcomes the opportunity to contribute to the evaluation of the Regulation (EU) 2017/745 on Medical Devices (MDR) and the Regulation (EU) 2017/746 on In-Vitro Diagnostic Medical Devices (IVDR).

EuropaBio, the industry association for biotechnology in Europe, welcomes the opportunity to contribute to the evaluation of Regulation (EU) 2017/745 on Medical Devices (MDR) and Regulation (EU) 2017/746 on In-Vitro Diagnostic Medical Devices (IVDR).

The EU Inc. proposal is a major step forward for the internal market, notably through digital formation, harmonised company law, and potentially the EUESO with taxation deferred to disposal. However, several targeted adjustments are needed to ensure it works for biotech and deeptech scaleups, spin-outs and founder-led companies.

Please find attached EuropaBio's input. (For complementary feedback and recommendations, please also refer to our consultation response to the European Innovation Act.) Biotechnology is one of the most critical technologies to Europe's autonomy, prosperity and ability to compete globally.

EuropaBio welcomes the revision of the EU Taxonomy Delegated Acts as a key opportunity to strengthen the bioeconomy's role in achieving EU environmental objectives. EuropaBio supports completing an inclusive approach to feedstocks eligible for sustainable finance that ensures predictable access to sustainably sourced biomass across the entire bioeconomy, while appropriately recognising the specificities of biotech…

EuropaBio welcomes the revision of the EU Taxonomy Delegated Acts as a key opportunity to strengthen the bioeconomys role in achieving EU environmental objectives. To maximise impact, the review should: 1) Adopt a more inclusive approach to feedstocks eligible for sustainable financing mechanisms 2) Distinguish biotechnology from conventional processes, as highlighted in the EU Bioeconomy Strategy More details…

EuropaBio represents the European biotechnology industry, including small and medium-sized enterprises, startups, scale-ups, established companies and European national and regional biotech associations. EuropaBio supports the objectives of the European Biotech Act and sets out chapter-by-chapter recommendations in the attached paper. Some of the main positions are as follows.

EuropaBio welcomes the introduction of targeted improvements in the Directive. It supports the objective of ensuring a high level of safety for human health and the environment while stimulating and advancing innovation, competitiveness and legal certainty.

Biotechnologies play an essential role for the delivery of EU objectives for competitive, healthy, resilient and sustainable economies and societies. Future-proofing fundamental frameworks across all biotech applications including healthcare, agri-food supply chains, manufacturing processes, chemicals and consumer goods, is critical.

The Biotech Act II shall complete the stated ambition from the European Commission and Member States for a far-reaching and multi-sector legislation. It should recognise EU advance through Biotech Act I in key aspects of biotechnology and extend these to the full delivery of biomanufacturing as central to Europes economic, supply chain and sustainable future.

Europe is at a critical point in shaping its innovation agenda. Despite world-class science and a strong research base, too many promising ideas fail to reach the market. Innovative companies, especially in biotechnology, face structural barriers to finance, talent and cross-border growth.

EuropaBio considers the Advanced Materials Act a timely and strategic initiative to reinforce biotechnologys role in building Europes clean, competitive and resilient industrial base. To maximise impact, the Act should: 1) Fully integrate biotechnology as a design, production and scaleup pathway for advanced materials; 2) Enable industrial deployment through expanded biomanufacturing capacity, predictable regulatory…